Stockscreener 앱 받기
1.74
2.25%
-0.04
시간 외 거래:
1.71
-0.03
-1.72%
Precigen Inc 주식(PGEN)의 최신 뉴스
Precigen Gene Therapy Pioneer Reveals 2024 Performance: Key Financial Results Coming March 19 - StockTitan
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Financial Times
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World
Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World
Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha
FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia
FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia
FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™
Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals
Precigen gets FDA Priority Review for its respiratory tract tumor treatment - MSN
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update By Investing.com - Investing.com South Africa
Precigen Says FDA Accepts for Priority Review Application for Recurrent Respiratory Papillomatosis Treatment - Marketscreener.com
Precigen shares surge on FDA priority review for PRGN-2012 By Investing.com - Investing.com Australia
FDA advances Precigen's gene therapy for respiratory disease By Investing.com - Investing.com Canada
Precigen shares surge on FDA priority review for PRGN-2012 - Investing.com India
FDA advances Precigen's gene therapy for respiratory disease - Investing.com India
FDA advances Precigen’s gene therapy for respiratory disease - Investing.com
Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment - MarketWatch
FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire
Should You Invest in Precigen (PGEN)? - MSN
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy? - Nasdaq
Precigen (NASDAQ:PGEN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Precigen (NASDAQ:PGEN) Stock Price Up 8.4%What's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Set Precigen, Inc. (NASDAQ:PGEN) PT at $7.00 - Armenian Reporter
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen (NASDAQ:PGEN) Hits New 52-Week HighHere's What Happened - MarketBeat
Will Precigen's Treatment For Recurrent Respiratory Papillomatosis Cross The FDA Finish Line? - RTTNews
SG Americas Securities LLC Acquires 12,578 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World
PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth - MSN
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Iridian Asset Management LLC CT - MarketBeat
These Numbers Prove Just How Vibrant The Precigen Inc (NASDAQ: PGEN) Stock Has Been - Stocks Register
Precigen (NASDAQ:PGEN) Shares Up 7.8%Here's Why - MarketBeat
Precigen stock slides after pricing stock offering to raise $30 million - MSN
Exploring 3 High Growth Tech Stocks in the United States - Simply Wall St
Precigen Inc (NASDAQ: PGEN): Performance Review And Forecast - Marketing Sentinel
Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha
0.55%
1.89%
자본화:
|
볼륨(24시간):